Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chemotherapy
Biotech
Corcept's phase 3 cancer win sends stock skyrocketing 85%
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone.
Gabrielle Masson
Mar 31, 2025 10:25am
Boston Scientific to buy chemo pump implant for liver tumors
Nov 25, 2024 12:00pm
Approved IBS drug may help overcome prostate cancer resistance
Jan 22, 2024 11:00am
Chemo drug boosts Daiichi Sankyo ADC in prostate cancer models
Nov 16, 2023 7:35am
Cancer pill works like a snowstorm shutting down an airport
Aug 1, 2023 11:45am
Gene therapy reduces chronic pain and chemo-induced neuropathy
Jul 31, 2023 9:30am
